PROCF.US Sofgen Pharma S.A.

Healthcare Drug Manufacturers - Specialty & Generic USA Stocks
0.0125 USD
Close of Nov 17, 2026
0.0001 0.0251
Market cap
USD 29.2M
P/E
-
P/B
66.68x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is PROCF.US undervalued?

Graham number

The Graham number of Sofgen Pharma S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sofgen Pharma S.A. fundamental analysis

No fundamental analysis for Sofgen Pharma S.A. yet.

Sofgen Pharma S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sofgen Pharma S.A.

Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company develops and manufactures Softgel and related technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands; and Softgel pharmaceutical…

Full company profile